FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Buggisch

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Living Beings

Hepacivirus

Physiology

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Viola Knop; Bernd Möller; Konrad Neumann; Jens Rasenack; Christoph Sarrazin; Ulrich Spengler; Gerlinde Teuber; Stefan Zeuzem; Peter Buggisch; Tilman Gerlach; Holger Hinrichsen; Hartwig Klinker; Thomas Berg
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Armando Santoro; Roland M Schmid; Brian Schwartz; Morris Sherman; Jörg Trojan; Jean Luc Van Laethem; Hans Van Vlierberghe; Reinhard Von Roemeling; Alan Weiss; Lorenza Rimassa; Stefania Salvagni; Giovanni Abbadessa; Corrado Boni; Ivan Borbath; Peter Buggisch; Yinpu Chen; Luca Cicalese; Bruno Daniele; Antonio Gasbarrini; Guido Gerken; Cesare Gridelli; Ziad Hassoun; Frank T Kolligs; Maria E Lamar; Monica Lencioni; Steven Miles; Nicola Personeni; Camillo Porta
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Martin Schaefer; Thomas Schlaepfer; Ulrich Spengler; Hans Weidenbach; Stefan Zeuzem; Thomas F Baumert; Peter Buggisch; Thomas Discher; Susanne Effenberger; Astrid Friebe; Gwendolyn Fromm; Andreas Heinz; Loni Heinze; Viola Knop; Klaus Lieb; Ralph Link; Konrad Neumann; Johann Ockenga; Jens Reimer; Michael Rentrop; Rahul Sarkar; Thomas Berg
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Buggisch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Viola Knop; Bernd Möller; Konrad Neumann; Jens Rasenack; Christoph Sarrazin; Ulrich Spengler; Gerlinde Teuber; Stefan Zeuzem; Peter Buggisch; Tilman Gerlach; Holger Hinrichsen; Hartwig Klinker; Thomas Berg
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Annals of hepatology 2013;12(2):190-8.
2013: Armando Santoro; Roland M Schmid; Brian Schwartz; Morris Sherman; Jörg Trojan; Jean Luc Van Laethem; Hans Van Vlierberghe; Reinhard Von Roemeling; Alan Weiss; Lorenza Rimassa; Stefania Salvagni; Giovanni Abbadessa; Corrado Boni; Ivan Borbath; Peter Buggisch; Yinpu Chen; Luca Cicalese; Bruno Daniele; Antonio Gasbarrini; Guido Gerken; Cesare Gridelli; Ziad Hassoun; Frank T Kolligs; Maria E Lamar; Monica Lencioni; Steven Miles; Nicola Personeni; Camillo Porta
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
The lancet oncology 2013;14(1):55-63.
2012: Martin Schaefer; Thomas Schlaepfer; Ulrich Spengler; Hans Weidenbach; Stefan Zeuzem; Thomas F Baumert; Peter Buggisch; Thomas Discher; Susanne Effenberger; Astrid Friebe; Gwendolyn Fromm; Andreas Heinz; Loni Heinze; Viola Knop; Klaus Lieb; Ralph Link; Konrad Neumann; Johann Ockenga; Jens Reimer; Michael Rentrop; Rahul Sarkar; Thomas Berg
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Annals of internal medicine 2012;157(2):94-103.
2012: Jorg Petersen; Vlad Ratziu; Christoph Sarrazin; Jan Schollmeyer; Martina Sterneck; Heiner Wedemeyer; Fabien Zoulim; Maria Buti; Harry L A Janssen; Pietro Lampertico; Marc Lutgehetmann; Thomas Berg; Ashley Brown; Peter Buggisch
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
Journal of hepatology 2012;56(3):520-6.
2012: Stefan Zeuzem; Kosh Agarwal; Sarah Arterburn; Peter Buggisch; yves horsmans; Hartwig Klinker; Steven Knox; Michael P Manns; Patrick Marcellin; John G McHutchison; Hongmei Mo; Christophe Moreno; David Oldach; Daniel Sereni; Jean-Pierre Zarski; Graham R Foster
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology (Baltimore, Md.) 2012;55(3):749-58.
2012: Patrice Cacoub; Nicolas Dupin; Geoffrey Dusheiko; Christophe Hézode; Jann Lübbe; Odile Picard; Ramon Pujol; Marc Bourlière; Peter Buggisch; Siegfried Segaert; Bing Thio; Jean-Claude Roujeau
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Journal of hepatology 2012;56(2):455-63.
2011: Johannes Wiegand; Stephan Böhm; Peter Buggisch; Tilman Gerlach; Holger Hinrichsen; Hartwig Klinker; Bernd Möller; Konrad Neumann; Jens Rasenack; Christoph Sarrazin; Ulrich Spengler; Gerlinde Teuber; Viola Weich; Thomas Berg
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(11):1111-4.
2011: Christoph Sarrazin; Ewert Schulte-Frohlinde; Susanne Schwendy; Gerlinde Teuber; Robert Thimme; Stefan Zeuzem; Wulf O Boecher; Peter Buggisch; Nektarios Dikopoulos; Jens Encke; Tobias Goeser; Eva Herrmann; Hartwig Klinker; Bernd Möller; Renate Prinzing; Thomas Berg
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Gastroenterology 2011;141(5):1656-64.
2011: Michael Manns; Stefan Mauss; Ismail Merican; Thomas H Müller; Lisa D Pedicone; Martin Rössle; Ajit Sood; Saif Abu-Mouch; Peter Buggisch; Rongdean Chen; Markus Cornberg; Rab Faruqi; Holger Hinrichsen; Andrzej Horban; Yaron Ilan; Hartwig Klinker; Yoav Lurie; Christoph Welsch; Stefan Zeuzem; Heiner Wedemeyer
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Journal of hepatology 2011;55(3):554-63.
2011: Julian Schulze Zur Wiesch; Neele Pudelski; Lena Hoepner; Michael Supplieth; Peter Buggisch; Ansgar W Lohse; Stefan Lüth
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
Hepatology (Baltimore, Md.) 2011;53(4):1405-6; author reply 1407.
2011: Daniel Benten; Rainer H Böger; Peter Buggisch; Veronica Franco; Charlotte A Gaydos; Andreas Koops; Ansgar W Lohse; Stuart C Ray; julian schulze zur wiesch; Karsten Sydow; Helen Won; Ashwin Balagopal
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
BMC gastroenterology 2011;11():107.
2011: E Jenny Heathcote; Patrick Marcellin; Maria Buti; Edward Gane; Robert A De Man; Zahary Krastev; George Germanidis; Samuel S Lee; Robert Flisiak; Kelly Kaita; Michael Manns; Iskren Kotzev; Konstantin Tchernev; Peter Buggisch; Frank Weilert; Oya Ovunc Kurdas; Mitchell L Shiffman; Huy Trinh; Selim Gurel; Andrea Snow-Lampart; Katyna Borroto-Esoda; Elsa Mondou; Jane Anderson; Jeff Sorbel; Franck Rousseau
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Gastroenterology 2011;140(1):132-43.
2010: Florian van Bommel; Robert A de Man; Heiner Wedemeyer; Katja Deterding; Jörg Petersen; Peter Buggisch; Andreas Erhardt; Dietrich Hüppe; Kerstin Stein; Jörg Trojan; Christoph Sarrazin; Wulf O Böcher; Ulrich Spengler; Hermann E Wasmuth; Jurrien G P Reinders; Bernd Möller; Peter Rhode; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
Hepatology (Baltimore, Md.) 2010;51(1):73-80.
2009: julian schulze zur wiesch; Dorothea Pieper; Ingrid Stahmer; Thomas Eiermann; Peter Buggisch; Ansgar Lohse; Joachim Hauber; Jan van Lunzen
Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(3):466-72.
2009: Thomas Berg; Viola Weich; Gerlinde Teuber; Hartwig Klinker; Bernd Möller; Jens Rasenack; Holger Hinrichsen; Tilman Gerlach; Ulrich Spengler; Peter Buggisch; Heike Balk; Myrga Zankel; Konrad Neumann; Christoph Sarrazin; Stefan Zeuzem
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
Hepatology (Baltimore, Md.) 2009;50(2):369-77.
2009: Katja Deterding; Johannes Wiegand; N Grüner; A Hahn; Elmar Jäckel; M C Jung; Peter Buggisch; P Galle; Thomas Berg; H Hinrichsen; Andrej Potthoff; Stefan Zeuzem; Markus Cornberg; Michael P Manns; Heiner Wedemeyer
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Zeitschrift für Gastroenterologie 2009;47(6):531-40.
2008: Patrick Marcellin; E Jenny Heathcote; Maria Buti; Ed Gane; Robert A de Man; Zahary Krastev; Georgios Germanidis; Sam S Lee; Robert Flisiak; Kelly Kaita; Michael Manns; Iskren Kotzev; Konstantin Tchernev; Peter Buggisch; Frank Weilert; Oya Ovung Kurdas; Mitchell L Shiffman; Huy Trinh; Mary Kay Washington; Jeff Sorbel; Jane Anderson; Andrea Snow-Lampart; Elsa Mondou; Joe Quinn; Franck Rousseau
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
The New England journal of medicine 2008;359(23):2442-55.
2008: Michael von Wagner; Wolf Peter Hofmann; Gerlinde Teuber; Thomas Berg; Tobias Goeser; Ulrich Spengler; Holger Hinrichsen; Hans Weidenbach; Guido Gerken; Michael Manns; Peter Buggisch; Eva Herrmann; Stefan Zeuzem
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Hepatology (Baltimore, Md.) 2008;48(5):1404-11.
2008: Juliane Halangk; Christoph Sarrazin; Konrad Neumann; Gero Puhl; Tobias Mueller; Gerlinde Teuber; Hartwig Klinker; Holger Hinrichsen; Peter Buggisch; Olfert Landt; Viola Weich; Alexandra Bergk; Bertram Wiedenmann; Peter Neuhaus; Thomas Berg; Heiko Witt
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
Journal of hepatology 2008;49(3):339-45.
2008: Maribel Rodríguez-Torres; Sugantha Govindarajan; Ricard Solá; Nathan Clumeck; Eduardo Lissen; Mário Pessôa; Peter Buggisch; Janice Main; Jean Depamphilis; Douglas T Dieterich
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.
Journal of hepatology 2008;48(5):756-64.
2007: M Steffen; Markus Cornberg; Peter Buggisch
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.
Hepato-gastroenterology 2007;54(80):2368-72.
2007: Bernd Kronenberger; Thomas Berg; Eva Herrmann; Holger Hinrichsen; Tilman Gerlach; Peter Buggisch; Ulrich Spengler; Tobias Goeser; Samer Nasser; Karsten Wursthorn; Gerd R Pape; Uwe Hopf; Stefan Zeuzem
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
European journal of gastroenterology & hepatology 2007;19(8):639-46.
2007: Johannes Wiegand; Markus Cornberg; Nuray Aslan; Verena Schlaphoff; Christoph Sarrazin; Anne Kubitschke; Peter Buggisch; Ayse Ciner; Elmar Jaeckel; Michael P Manns; Heiner Wedemeyer
Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.
Antiviral therapy 2007;12(3):303-16.
2006: Eduardo Lissen; Nathan Clumeck; Ricardo Sola; Maria C Mendes-Correa; Julio Montaner; Mark Nelson; Jean DePamphilis; Mário Pessôa; Peter Buggisch; Janice Main; Douglas T Dieterich
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
AIDS (London, England) 2006;20(17):2175-81.
2006: Karsten Wursthorn; Marc Lutgehetmann; Maura Dandri; Tassilo Volz; Peter Buggisch; Bernhard Zollner; Thomas Longerich; Peter Schirmacher; Frauke Metzler; Myrga Zankel; Conrad Fischer; Graeme Currie; Carol L Brosgart; Jörg Petersen
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Hepatology (Baltimore, Md.) 2006;44(3):675-84.
2006: Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Gastroenterology 2006;130(4):1086-97.
2006: Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
Hepatology (Baltimore, Md.) 2006;43(2):250-6.
2006: Karsten Wursthorn; Peter Buggisch; Marc Lutgehetmann; Bernhard Zollner; Jörg Petersen
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Antiviral therapy 2006;11(5):647-52.
2005: Peter Nielsen; Rosemarie Kongi; Peter Buggisch; Roland Fischer
Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate.
Arzneimittel-Forschung 2005;55(7):376-81.
2004: Thomas Berg; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Reinhart Zachoval; Stefan Zeuzem
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
Hepatology (Baltimore, Md.) 2004;39(5):1456-7; author reply 1457-8.
2004: Silvia Mascheretti; Holger Hinrichsen; S Ross; Peter Buggisch; Jochen Hampe; Ulrich R Foelsch; Stefan Schreiber
Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients.
Clinical and experimental immunology 2004;136(2):328-33.
2003: Peter Nielsen; Roland Fischer; Peter Buggisch; Gritta E Janka-Schaub
Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases.
British journal of haematology 2003;123(5):952-3.
2003: Markus Reiser; Peter Buggisch; Johannes Grossmann; Karsten Koop; Karsten Wursthorn; Wolff Schmiegel
First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
European journal of gastroenterology & hepatology 2003;15(12):1299-304.
2003: Thomas Berg; Bernd Kronenberger; Holger Hinrichsen; Tilman Gerlach; Peter Buggisch; Eva Herrmann; Ulrich Spengler; Tobias Goeser; Samer Nasser; Karsten Wursthorn; Gerd R Pape; Uwe Hopf; Stefan Zeuzem
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Hepatology (Baltimore, Md.) 2003;37(6):1359-67.
1997: Wolff Schmiegel; Jan Schmielau; D Henne-Bruns; H Juhl; C Roeder; Peter Buggisch; A Onur; B Kremer; H Kalthoff; E V Jensen
Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(23):12622-6.